✦ LIBER ✦

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

✍ Scribed by Ridderstråle, Martin (author);Andersen, Knut Robert (author);Zeller, Cordula (author);Kim, Gabriel (author);Woerle, Hans J. (author);Broedl, Uli C. (author)

Book ID: 124101406
Publisher: Lancet Publishing Group
Year: 2014
Tongue: English
Weight: 597 KB
Volume: 2
Category: Article
ISSN: 2213-8587
DOI: 10.1016/S2213-8587(14)70120-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of empagliflozin and glimepir

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

✍ Ridderstråle, Martin (author);Andersen, Knut Robert (author);Zeller, Cordula (au 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 597 KB

Empagliflozin monotherapy with sitaglipt

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

✍ Roden, Michael; Weng, Jianping; Eilbracht, Jens; Delafont, Bruno; Kim, Gabriel; 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 375 KB

Efficacy and safety of canagliflozin ver

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

✍ Cefalu, William T; Leiter, Lawrence A; Yoon, Kun-Ho; Arias, Pablo; Niskanen, Leo 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 489 KB

Rationale, design and baseline character

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

✍ Ridderstråle, Martin; Svaerd, Robbyna; Zeller, Cordula; Kim, Gabriel; Woerle, Ha 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 289 KB

2-year efficacy and safety of linaglipti

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

✍ Baptist Gallwitz; Julio Rosenstock; Thomas Rauch; Sudipta Bhattacharya; Sanjay P 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 289 KB

Linagliptin monotherapy in type 2 diabet

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

✍ Barnett, A. H.; Patel, S.; Harper, R.; Toorawa, R.; Thiemann, S.; von Eynatten, 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 619 KB